A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Recruiting

Phase 3

RitlecitinibA Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Sponsor:

Pfizer

Code:

NCT07029828

Conditions

Severe Alopecia Areata

Eligibility Criteria

Sex: All

Age: 6 - 14

Healthy Volunteers: Not accepted

Interventions

Ritlecitinib higher dose

Ritlecitinib lower dose

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Pfizer on 2025-10-01.